UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Journal of molecular medicine (Berlin, Germany), ISSN 0946-2716, 9/2016, Volume 94, Issue 9, pp. 979 - 991
Human Genetics | Oncolytic viruses | Biomedicine | Immunotherapy | Internal Medicine | Molecular Medicine | Immune checkpoint inhibitors | Combination therapy | Cancer | Genetics & Heredity | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Gene Transfer Techniques | Genetic Therapy | Immunomodulation - drug effects | Gene Expression | Immunotherapy - methods | Genetic Vectors - administration & dosage | Immunotherapy, Adoptive | Humans | Oncolytic Viruses - genetics | Treatment Outcome | Clinical Trials as Topic | Combined Modality Therapy | Molecular Targeted Therapy | Biomarkers, Tumor | Genetic Vectors - genetics | Oncolytic Virotherapy - methods | Neoplasms - therapy | Animals | Neoplasms - genetics | Antineoplastic Agents, Immunological - therapeutic use | Neoplasms - immunology | Neoplasms - pathology | Transgenes | Care and treatment | Health aspects | Methods | Index Medicus
Journal Article
BioMed research international, ISSN 2314-6133, 8/2017, Volume 2017, pp. 3620510 - 14
Life Sciences & Biomedicine | Biotechnology & Applied Microbiology | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Virus Replication - genetics | Humans | Cercopithecus aethiops | Apoptosis - genetics | Vaccinia virus - genetics | Cell Death - genetics | Neoplasms - genetics | DNA Fragmentation | Caspase 3 - genetics | Apoptosis Regulatory Proteins - genetics | Membrane Potential, Mitochondrial - genetics | Female | Phosphatidylserines - genetics | bcl-2-Associated X Protein - genetics | Caspase 7 - genetics | Transgenes - genetics | Antineoplastic Agents | HSP70 Heat-Shock Proteins - genetics | Oncolytic Viruses - genetics | Up-Regulation - genetics | Mice, SCID | Genetic Vectors - genetics | Granulocyte-Macrophage Colony-Stimulating Factor - genetics | Animals | Cell Line, Tumor | Biomarkers, Tumor - genetics | Mice | Physiological aspects | Genetic aspects | Genetic engineering | DNA viruses | Recombinant proteins | Methods | Apoptosis | Biotechnology | Bax protein | Viruses | Genomes | Activation | Vaccines | Immunity | HMGB1 protein | Caspase-3 | Cancer therapies | Anticancer properties | Proteins | Mitochondria | Calreticulin | Immunotherapy | DNA fragmentation | Cell cycle | Gangrene | Oncolysis | Membrane potential | Transgenes | Phosphatidylserine | Deoxyribonucleic acid--DNA | Killing | Medical research | Granulocyte-macrophage colony-stimulating factor | Tumor cells | Mortality | Markers | Caspase | Hsp70 protein | Breast cancer | Virology | Caspase-7 | Immunogenicity | Cellular biology | Cell death | Adenoviruses | Antitumor activity | Recombinants | Cancer | Index Medicus
Journal Article
Molecular therapy, ISSN 1525-0016, 02/2014, Volume 22, Issue 2, pp. 420 - 429
Genetics & Heredity | Life Sciences & Biomedicine | Biotechnology & Applied Microbiology | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Lung Neoplasms - mortality | Cytopathogenic Effect, Viral | Vesiculovirus - immunology | Neoplasms - therapy | Lung Neoplasms - secondary | Melanoma, Experimental | Neoplasms - genetics | Vesiculovirus - genetics | Female | Viral Tropism | Lung Neoplasms - genetics | Gene Expression | Genetic Vectors - immunology | Neoplasms - mortality | Immunization, Secondary - methods | Oncolytic Viruses - genetics | Treatment Outcome | Lung Neoplasms - therapy | Genetic Vectors - genetics | Cancer Vaccines - immunology | Lung Neoplasms - immunology | Animals | Intramolecular Oxidoreductases - genetics | Neoplasms - immunology | Rhabdoviridae - immunology | Oncolytic Viruses - immunology | Mice | Rhabdoviridae - genetics | CD8-Positive T-Lymphocytes - immunology | Neoplasms - pathology | Index Medicus | Original
Journal Article
Cancer science, ISSN 1347-9032, 10/2016, Volume 107, Issue 10, pp. 1373 - 1379
herpes simplex virus | Clinical trial | oncolytic immunotherapy | G47 | oncolytic virus | Life Sciences & Biomedicine | Oncology | Science & Technology | Immunotherapy - methods | Genetic Vectors - administration & dosage | Humans | Oncolytic Viruses - genetics | Treatment Outcome | Clinical Trials as Topic | Genetic Vectors - genetics | Immunotherapy - adverse effects | Oncolytic Virotherapy - methods | Neoplasms - therapy | Animals | Genetic Engineering | Neoplasms - genetics | Oncolytic Virotherapy - adverse effects | Genetic Therapy - adverse effects | Genetic Therapy - methods | Oncology, Experimental | Immunotherapy | Genetically modified organisms | Melanoma | Genetic engineering | Research | Drug therapy | Health aspects | Drug approval | Cancer | Brain cancer | Genes | Glioblastoma | Clinical trials | Herpes simplex | Hepatocellular carcinoma | Viruses | Genomes | Cancer therapies | Tropical diseases | Hepatitis | Oncolysis | Cytokines | Research & development--R&D | Bladder cancer | Patients | Fever | Immune checkpoint | Adenoviruses | Head and neck cancer | Head & neck cancer | Viral infections | Tumors | Index Medicus | Review
Journal Article
Molecular therapy, ISSN 1525-0016, 05/2017, Volume 25, Issue 5, pp. 1107 - 1116
competitive landscape | oncolytic virotherapy | viro-immuno-oncology | T-VEC | Genetics & Heredity | Life Sciences & Biomedicine | Biotechnology & Applied Microbiology | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Lymph Nodes - pathology | Humans | Mutant Chimeric Proteins - genetics | Plasmacytoma - genetics | Multiple Myeloma - immunology | Plasmacytoma - immunology | Plasmacytoma - pathology | Measles virus - genetics | Multiple Myeloma - therapy | Antigen Presentation | Melanoma - genetics | Mutant Chimeric Proteins - metabolism | T-Lymphocytes - pathology | Skin Neoplasms - pathology | Antigens, Neoplasm - genetics | Oncolytic Virotherapy - trends | Genetic Vectors - chemistry | Herpesvirus 1, Human - metabolism | Skin Neoplasms - immunology | Skin Neoplasms - therapy | Antigens, Neoplasm - immunology | Genetic Vectors - metabolism | Oncolytic Viruses - genetics | Lymph Nodes - immunology | Melanoma - pathology | Oncolytic Virotherapy - methods | Multiple Myeloma - pathology | Measles virus - metabolism | Melanoma - immunology | Oncolytic Viruses - immunology | Plasmacytoma - therapy | Skin Neoplasms - genetics | Herpesvirus 1, Human - genetics | T-Lymphocytes - immunology | Melanoma - therapy | Multiple Myeloma - genetics | Tumor cells | Immunomodulation | Melanoma | Antibodies | Viruses | Lymphocytes T | Kinases | Macrophages | Lymph nodes | Skin cancer | Metastases | Immune checkpoint | Immunotherapy | Antigen (tumor-associated) | Oncolysis | Index Medicus | Review
Journal Article
Virus genes, ISSN 0920-8569, 10/2017, Volume 53, Issue 5, pp. 700 - 706
Retargeting | Medical Microbiology | Arming | Biomedicine | Adenovirus | Checkpoint inhibition | Conditional replication | Oncolytic virus | Plant Sciences | Virology | Genetics & Heredity | Life Sciences & Biomedicine | Science & Technology | Neoplasms - virology | Oncolytic Virotherapy - methods | Neoplasms - therapy | Animals | Humans | Adenoviridae - genetics | Oncolytic Viruses - genetics | Genetic Vectors - genetics | Genetic Therapy - methods | Virus diseases | Medical colleges | Viral proteins | Adenoviruses | Melanoma | Health aspects | Tumors | Cytolysis | Immune response | Immunostimulation | Immunotherapy | Lysis | Clinical trials | Oncolysis | Viruses | Index Medicus
Journal Article
Molecular therapy, ISSN 1525-0016, 04/2018, Volume 26, Issue 4, pp. 1008 - 1019
NDV | tumor immunology | oncolytic virus | pre-existing immunity | Newcastle Disease Virus | cancer immunotherapy | immuno-oncology | Genetics & Heredity | Life Sciences & Biomedicine | Biotechnology & Applied Microbiology | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | T-Lymphocyte Subsets - immunology | Genetic Vectors - administration & dosage | Humans | Genetic Vectors - adverse effects | Lymphocyte Activation - genetics | Lymphocyte Activation - immunology | Neoplasms - therapy | Melanoma, Experimental | Injections, Intralesional | Newcastle disease virus - immunology | Transgenes | Oncolytic Virotherapy - adverse effects | Disease Models, Animal | Adaptive Immunity | Gene Expression | Genetic Vectors - immunology | Oncolytic Viruses - genetics | Treatment Outcome | Genetic Vectors - genetics | Xenograft Model Antitumor Assays | Animals | Neoplasms - immunology | T-Lymphocyte Subsets - metabolism | Newcastle disease virus - genetics | Oncolytic Viruses - immunology | Cell Line, Tumor | Mice | Neoplasms - pathology | Genetic Therapy - adverse effects | Genetic Therapy - methods | Potentiation | Medical research | Antiviral agents | Immunoglobulins | Animal models | Immune response | Laboratories | Immune clearance | Melanoma | Viruses | Infections | FDA approval | Gene expression | Patients | Experiments | Ovarian cancer | Newcastle disease | Immunotherapy | Oncolysis | Viral infections | Immune system | Tumors | Index Medicus | Original
Journal Article